BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγon T cells

Autor: Mary J van Helden, Seline A Zwarthoff, Roel J Arends, Inge M J Reinieren-Beeren, Marc C B C Paradé, Lilian Driessen-Engels, Karin de Laat-Arts, Désirée Damming, Ellen W H Santegoeds-Lenssen, Daphne W J van Kuppeveld, Imke Lodewijks, Hugo Olsman, Hanke L Matlung, Katka Franke, Ellen Mattaar-Hepp, Marloes E M Stokman, Benny de Wit, Dirk H R F Glaudemans, Daniëlle E J W van Wijk, Lonnie Joosten-Stoffels, Jan Schouten, Paul J Boersema, Monique van der Vleuten, Jorien W H Sanderink, Wendela A Kappers, Diels van den Dobbelsteen, Marco Timmers, Ruud Ubink, Gerard J A Rouwendal, Gijs Verheijden, Miranda M C van der Lee, Wim H A Dokter, Timo K van den Berg

Publikováno v: van Helden, M J, Zwarthoff, S A, Arends, R J, Reinieren-Beeren, I M J, Paradé, M C B C, Driessen-Engels, L, de Laat-Arts, K, Damming, D S, Santegoeds-Lenssen, E W H, van Kuppeveld, D W J, Lodewijks, I, Olsman, H, Matlung, H L, Franke, K, Mattaar-Hepp, E, Stokman, M E M, de Wit, B, Glaudemans, D H R F, van Wijk, D E J W, Joosten-Stoffels, L, Schouten, J, Boersema, P J, van der Vleuten, M, Sanderink, J W H, Kappers, W A, van den Dobbelsteen, D, Timmers, M, Ubink, R, Rouwendal, G J A, Verheijden, G, van der Lee, M M C, Dokter, W H A & van den Berg, T K 2023, ' BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγon T cells ', Journal for Immunotherapy of Cancer, vol. 11, no. 4, jitc-2022-006567 . https://doi.org/10.1136/jitc-2022-006567

BackgroundPreclinical studies have firmly established the CD47-signal-regulatory protein (SIRP)α axis as a myeloid immune checkpoint in cancer, and this is corroborated by available evidence from the first clinical studies with CD47 blockers. Howeve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12f6e6308ed606888d418126a12792c8
https://research.vumc.nl/en/publications/67116c0e-064c-4154-86d3-6797beec296d

A Platform for the Generation of Site-Specific Antibody-Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines

Autor: Bas P. A. Kokke, C. Marco Timmers, Henri Johannes Spijker, Jan Schouten, Pascal Renart Verkerk, Wim H. A. Dokter, Ruud Coumans, Patrick G. Groothuis, Ruud Ubink, Patrick Henry Beusker, Miranda M. C. van der Lee, Gerry J. A. Ariaans, Marion Blomenrohr

Publikováno v: Bioconjugate chemistry. 31(9)

Engineering cysteines at specific sites in antibodies to create well-defined ADCs for the treatment of cancer is a promising approach to increase the therapeutic index and helps to streamline the manufacturing process. Here, we report the development

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b603a9b699c317b8c93e38029e508ca
https://pubmed.ncbi.nlm.nih.gov/32697078

Unraveling the Interaction between Carboxylesterase 1c and the Antibody–Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice

Autor: E Bos, Patrick G. Groothuis, Miranda M.C. van der Lee, Eef Hc Dirksen, Ruud Ubink, Kim Berentsen, David F. Egging, Ingrid Janssen, Olivier Raguin, Myrthe Rouwette, Eline Loosveld, Francis Bichat, Wim H. A. Dokter, Monique van der Vleuten, Tanja van Achterberg

Publikováno v: Molecular Cancer Therapeutics. 17:2389-2398

Carboxylesterase 1c (CES1c) is responsible for linker-drug instability and poor pharmacokinetics (PK) of several antibody–drug conjugates (ADC) in mice, but not in monkeys or humans. Preclinical development of these ADCs could be improved if the PK

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc1ba79e85bd8e8ae62d301e3941d452
https://doi.org/10.1158/1535-7163.mct-18-0329

Abstract 925: Introduction to the preclinical profile of SYD1875, a novel site-specifically conjugated duocarmycin-based 5T4-targeting antibody-drug conjugate

Autor: Kim Berentsen, Patrick G. Groothuis, Marion Blomenrohr, Ronald Christiaan Elgersma, Wim H. A. Dokter, Danielle Jacobs, Miranda van der Lee, Monique van der Vleuten, Ruud Coumans, Patrick Henry Beusker, Diels van den Dobbelsteen, Ruud Ubink

Publikováno v: Cancer Research. 81:925-925

5T4 is an oncofetal antigen with low expression in healthy tissues which is frequently overexpressed in different tumor types. Despite its overexpression in various malignancies and its association with poor prognosis, there are currently no marketed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2ba8489a01616ad01a2a8f3a6127680
https://doi.org/10.1158/1538-7445.am2021-925

Abstract 4043: SYD985 synergy with PARP inhibitors (PARPi) in human tumor cell lines and patient-derived xenografts (PDXs)

Autor: Danielle Jacobs, Miranda van der Lee, Patrick G. Groothuis, Fred Dijcks, Monique van der Vleuten, Wim H. A. Dokter, Jan H.M. Schellens, Ellen Mattaar, Eline Loosveld

Publikováno v: Cancer Research. 80:4043-4043

SYD985 is a HER2-targeting antibody-drug conjugate comprised of a cleavable linker and the prodrug seco-DUBA which, upon release, spontaneously rearranges to form the active toxin DUBA. DUBA covalently binds adenine in the DNA resulting in DNA damage

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1bec632bdc912c2144eb96fa1e0af067
https://doi.org/10.1158/1538-7445.am2020-4043